{"id":"cucart19","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CUCART19 works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering host cells and thereby inhibiting viral replication.","oneSentence":"CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:47.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT06462248","phase":"PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies","status":"RECRUITING","sponsor":"Chi Kong Li","startDate":"2024-06-01","conditions":"Lymphoma, Nonhodgkin, Leukemia, Lymphocytic","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anti-CD19 CAR-T"],"phase":"phase_2","status":"active","brandName":"CUCART19","genericName":"CUCART19","companyName":"Chi Kong Li","companyId":"chi-kong-li","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}